Sign in to view content

Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

Mark R. Barakat, MD

Video
Published 2022

Related

Rates of Post Intravitreal Anti-VEGF Injection Endophthalmitis: Management Strategies and Visual Acuity Outcomes From the AAO IRIS Registry
Alia K Durrani, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023
Prospective Evaluation of Pain and Inflammation Following Injection of Aflibercept or Ranibizumab in Patients With Diabetic Macular Edema: SOLAR Study
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2018

Category: Pharmacology

See more